John Evans

John Evans

CEOatBeam Therapeutics· In proxies 2021–2025

Pay in FY2025-9% from the year before · Beam Therapeutics stock +11.8% the same year

John Evans was paid $5.8M in FY2025 (Dec), down 9%. Beam Therapeutics stock rose 11.8% that year.

Pay$100 in the stock at the end of FY20 → $34
Pay is from the Summary Compensation Table of each Beam Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Beam TherapeuticsPublic company · 5 yr
    • CEO2021 – Present · 5 yrStock in role -67%
  2. Orbital Therapeutics, Inc.Public company
    • Director? – PresentNo stock prices for these years
  3. Prime Medicines Inc.Public company · 3 yr
    • Director2019 – 2022 · 3 yrNo stock prices for these years
  4. Verve TherapeuticsPublic company · 4 yr
    • Director2018 – 2022 · 4 yrNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?